A practical reference on lipodystrophy: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-03. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
The effect of botulinum toxin type-A on reducing and eliminating forehead wrinkles was first described and published by Richard Clark, MD, a plastic surgeon from Sacramento, California. In 1987 Clark was challenged with eliminating the disfigurement caused by only the right side of the forehead muscles functioning after the left side of the forehead was paralyzed during a facelift procedure. This patient had desired to look better from her facelift, but was experiencing bizarre unilateral right forehead eyebrow elevation while the left eyebrow drooped, and she constantly demonstrated deep expressive right forehead wrinkles while the left side was perfectly smooth due to the paralysis. Clark was aware that botulinum toxin was safely being used to treat babies with strabismus and he requested and was granted FDA approval to experiment with botulinum toxin to paralyze the moving and wrinkling normal functioning right forehead muscles to make both sides of the forehead appear the same. This study and case report of the cosmetic use of botulinum toxin to treat a cosmetic complication of a cosmetic surgery was the first report on the specific treatment of wrinkles and was published in the journal Plastic and Reconstructive Surgery in 1989. Editors of the journal of the American Society of Plastic Surgeons have clearly stated "the first described use of the toxin in aesthetic circumstances was by Clark and Berris in 1989." J. D. and J. A.
In the case of Annie Ee Yu Lian who was abused and murdered by her two friends, some Singaporeans were angered at the cruelty displayed by the offenders and felt that the sentences (which were between 14 and 16 years) for grievous hurt were too light, which prompted them to petition for harsher punishments; some even demanded for the death penalty to be imposed on the couple. In another case regarding the death of four-year-old Mohamad Daniel Mohamad Nasser due to child abuse perpetuated by his mother and her boyfriend, some Singaporeans felt that their sentences of ten to eleven years were too light and petitioned to the courts to sentence the couple to death. Younger generations of Singaporeans tend to have a more liberal approach towards drug use. The government, in response, has introduced education programmes on the dangers of drugs. There were cases of ex-drug convicts who also advocated against the use of drugs; some even agree that the death penalty was effective. A former trafficker once stated that in the past, he would always make sure the measurement of his delivered drugs were below the minimum amount to avoid capital punishment. A female prisoner and drug convict also spoke up about the death penalty while being interviewed in prison, where she was serving 26 years' jail since 2014. She agreed to the relevance and effect of the death penalty in stopping people from selling and taking drugs, as she knew how drug trafficking caused damage to families and inflict sufferings especially to the children of drug addicts.
== History == To a certain extent, medical practitioners have long been specialized. According to Galen, specialization was common among Roman physicians. The particular system of modern medical specialties evolved gradually during the 19th century. Informal social recognition of medical specialization evolved before the formal legal system. The particular subdivision of the practice of medicine into various specialties varies from country to country, and is somewhat arbitrary.
Sources: en.wikipedia.org
=== Modern Levantine groups with Israelite ancestry === Samaritans and Jews descend from the Israelites. With regard to the Jewish diaspora, it is held that each Jewish community originates from exiled Israelite settlement in various parts of the world, particularly as a result of the Jewish–Roman wars. It is also argued that some Palestinian people are similarly descended from those Israelites who were not exiled from the region and who consequently converted to Christianity under the Byzantine Empire and then to Islam following the Arab conquest of the Levant, except for Palestinian Jews and present-day Samaritans.
In World War I Calabria dispatched five brigades to the effort, most notably the Catanzaro Brigade. It was formed of the 141st and 142nd regiments, composed almost exclusively of Calabrians. It was one of the units most committed by the Royal Army in the war. Part of the Third Army under the command of the king's cousin the Duke of Aosta, it participated in the Third Battle of the Isonzo, where, on Monte San Michele, between 17 and 26 October 1915, it lost almost half of its personnel (about 6,000 men). In addition, during the Strafexpedition of June 1916, the 141st Brigade Regiment lost 38% of its components, with 333 casualties.
=== Financial performance === GoodRx was founded in Santa Monica, California in 2011. GoodRx experienced substantial growth in net income in 2017 ($9 million), 2018 ($44 million), and 2019 ($66 million), but recorded a loss of $293.6 million in 2020 due to IPO-related expenses. In September 2020, GoodRx went public on the Nasdaq under the ticker symbol GDRX. The company priced its initial public offering at $33 per share, above the expected range of $24 to $28, raising more than $1.1 billion at an initial valuation of approximately $12.7 billion. In the first half of 2020, the company reported revenues of $257 million and net income of $55 million. GoodRx generated $745.4 million in revenue for the full year 2021, a 35.36% increase over 2020. During the first half of 2021, the company's share price declined by 10.7%. The decline was attributed to increased competition in online pharmacy services and slower user growth. GoodRx reported full-year revenue of $766.6 million, with adjusted EBITDA reaching $213.5 million, exceeding guidance in the fourth quarter. GoodRx reported that 41% of prescriptions filled using its coupons were newly adherent, meaning they would not have been filled without the service. GoodRx reported a full-year 2023 revenue of $750.3 million, a decrease of 2.1% from 2022. However, its fourth-quarter revenue increased by 7% year-over-year. GoodRx achieved an Adjusted EBITDA of $217.4 million for the year and an Adjusted EBITDA Margin of 28.6%.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.